DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Saroglitazar
Saroglitazar
A Role of Peroxisome Proliferator‐Activated Receptor Γ in Non‐Alcoholic Fatty Liver Disease
'Made in India': the Saroglitazar Story
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands As Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
Oral Anti-Diabetic Agents-Review and Updates
Stembook 2018.Pdf
Role of Glitazars in Atherogenic Dyslipidemia and Diabetes: Two Birds with One Stone?
Biological and Chemical Investigation of Panamanian Plants for Potential Utility Against Metabolic Syndrome
Exploration and Development of PPAR Modulators in Health and Disease: an Update of Clinical Evidence
Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly Ppara Agonist with Moderate Pparc Agonist Activity in Healthy Human Subjects
Product Monograph
Extended Commentary from the American Diabetes Association
WO 2016/066668 Al 6 May 2016 (06.05.2016) P O P C T
Saroglitazar in Patients with Non-Alcoholic Fatty Liver Disease And
The Effect of Antidiabetic Medications on Non-Alcoholic Fatty Liver Disease
PPAR Gamma and Viral Infections of the Brain
(12) United States Patent (10) Patent No.: US 9,526,728 B2 Klein Et Al
Effectiveness of the PPAR Agonist Saroglitazar in Nonalcoholic Steatohepatitis: Positive Data from Preclinical & Clinical Studies
Product Information
Top View
Saroglitazar: a New Drug to Treat Diabetic Hypertriglyceridemia Review
Synthetic and Natural Peroxisome Proliferator‑Activated Receptor (PPAR) Agonists As Candidates for the Therapy of the Metabolic Syndrome
Guidelines for Management of Type 2 Diabetes 2018
IJBCP International Journal of Basic & Clinical Pharmacology Pattern of Anti-Diabetic Drugs Prescribed for Type 2 Diabete
Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?
ICMR GUIDELINES for MANAGEMENT of TYPE 2 DIABETES 2018 S.NO CONTENTS PAGE NO. PREAMBLE SECTION 1 : INTRODUCTION 1.1 Definition 1
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Late Breaking Abstracts
SEC (Endocrinology & Metabolism) Made in Its 72Nd Meeting Held On
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
Biocatalyzed Synthesis of Antidiabetic Drugs: a Review
8. JCD Vol 3 No 1 Quiz
Fatty Liver Disease (Nafld/Nash)
Effect of a Dual PPAR Α/Γ Agonist on Insulin Sensitivity in Patients Of
A Prospective, Multicentre, Single Arm Clinical Study to Evaluate the Effect
Saroglitazar, a Novel Cardiometabolic Agent for Diabetic Dyslipidemia – a Review
Saroglitazar: a New Drug to Treat Diabetic
Saroglitazar: India's Answer to Diabetic Dyslipidemia
Saroglitazar
Diabetic Dyslipidemia